New Online Commentary in UroToday on Fexapotide BPH Clinical Trial Results Publication in World Journal of Urology
April 10 2018 - 10:00AM
A new online published commentary about Nymox’s (NASDAQ:NYMX)
Fexapotide 2018 clinical trial results publication in World Journal
of Urology has newly appeared today on UroToday in its "Beyond the
Abstract" section, along with the abstract of the World Journal of
Urology article. The additional commentary was authored by Dr. Neal
Shore, lead author of the peer review World Journal article, and
Dr. Ronald Tutrone, the first co-author of the article. The
Beyond the Abstract commentary is entitled “Fexapotide Triflutate:
Results of Long-Term Safety and Efficacy Trials of A Novel
Injectable Therapy For Symptomatic Prostate Enlargement - Beyond
the Abstract”. The World Journal of Urology article is entitled
"Fexapotide Triflutate: Results of Long-Term Safety and Efficacy
Trials of A Novel Injectable Therapy For Symptomatic Prostate
Enlargement" (https://doi.org/10.1007/s00345-018-2185-y).
According to the new "Beyond the Abstract"
commentary, "Fexapotide triflutate (FT) is a first in class protein
injectable designed for safe and relatively painless office
treatment of BPH. It works by selective promotion of apoptosis in
prostate glandular cells. FT is administered under transrectal
ultrasound visualization using a standard 22 gauge needle. Over
1700 patients and controls have been injected with FT since the
first U.S. clinical trials in 2002, and there have been no
molecular related adverse events described. There is no need for a
urinary catheter or anesthesia. Clinically significant improvements
from baseline symptoms may occur within 1-2 weeks.”
The commentary concludes, “Regarding a molecular
therapy for BPH, there continues to exist an unmet need for patient
treatment whereby symptoms can be effectively treated while
avoiding associated sexual dysfunction, catheterization and
significant anesthetic requirements. FT is in late stage
development and has potential to be a fundamentally new
addition to office based treatment for BPH patients.”
The new commentary also features a review and
illustration Figures.
The World Journal of Urology article was also
co-authored by Mitchell Efros, MD, FACS (Accumed Research, Garden
City, NY); Mohamed Bidair, MD (San Diego Clinical Trials, San
Diego, CA); Barton Wachs, MD (Atlantic Urology Medical Group, Long
Beach, CA); Susan Kalota, MD (Urological Associates of Southern
Arizona, Tucson, AZ); Sheldon Freedman, MD, FACS (Freedman Urology,
Las Vegas, NV); James Bailen, MD, FACS (First Urology, Louisville,
KY); Richard Levin, MD, FACS (Chesapeake Urology Research
Associates, Towson, MD); Stephen Richardson, MD (Jean Brown
Research, Salt Lake City, UT); Jed Kaminetsky, MD, FACS (University
Urology, New York, NY); Jeffrey Snyder, MD, FACS (Genitourinary
Surgical Consultants, Denver, CO); Barry Shepard, MD, FACS
(Urological Surgeons of Long Island, Garden City, NY);
Kenneth Goldberg, MD, FACS (U T Southwestern Dept of Urology,
Lewisville, TX); Alan Hay, MD, FACS (Willamette Urology, Salem,
OR); Steven Gange, MD, FACS (Summit Urology Group, Salt Lake City,
UT); Ivan Grunberger, MD, FACS (Brooklyn Urology, Brooklyn,
NY).
Nymox's lead drug Fexapotide has been in
development for over 10 years and has been tested by expert
clinical trial investigative teams in over 70 distinguished
clinical trial centers throughout the US, and has been found after
7 years of prospective placebo controlled double blind studies of
treatment of 995 U.S. men with prostate enlargement to not only
show clinically meaningful and durable relief of BPH symptoms, but
also to show a major reduction in the incidence of prostate cancer,
compared to placebo and compared to the known and expected normal
incidence of the disease. The same clinical program has also shown
in a long-term blinded placebo group study an 82-95% reduction in
the number of these patients who required surgery after they
received Fexapotide in the trial, as compared to patients who did
not receive Fexapotide but instead later received conventional
approved BPH treatments (p<.0001).
For more information please
contact info@nymox.com or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Nymox, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including statements regarding the need for new options to
treat BPH and prostate cancer, the potential of Fexapotide to treat
BPH and prostate cancer and the estimated timing of further
developments for Fexapotide. Such forward-looking statements
involve substantial risks and uncertainties that could cause our
clinical development program, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in
the clinical drug development process, including the regulatory
approval process, the timing of Nymox's regulatory filings, Nymox's
substantial dependence on Fexapotide, Nymox's commercialization
plans and efforts and other matters that could affect the
availability or commercial potential of Fexapotide. Nymox
undertakes no obligation to update or revise any forward looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of Nymox in general, see Nymox's current
and future reports filed with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 20-F for the year
ended December 31, 2017, and its Quarterly Reports.
For Further Information
Contact:Erik DanielsenNymox Pharmaceutical
Corporation1-800-93NYMOXwww.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Sep 2023 to Sep 2024